Related Experiment Video
Updated: Jan 20, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Mutations in KIRREL1, a slit diaphragm component, cause steroid-resistant nephrotic syndrome
Ashish K Solanki1, Eugen Widmeier2, Ehtesham Arif1
1Department of Medicine, Nephrology Division, Medical University of South Carolina, Charleston, South Carolina, USA.
Steroid-resistant nephrotic syndrome (SRNS) can be caused by mutations in the KIRREL1 gene, affecting kidney filtration. Defective KIRREL1 protein localization impairs podocyte function, leading to chronic kidney disease.
Area of Science:
- Nephrology
- Genetics
- Molecular Biology
Background:
- Steroid-resistant nephrotic syndrome (SRNS) is a significant cause of chronic kidney disease, often progressing to end-stage renal disease.
- Over 58 monogenic causes of SRNS have been identified, with many implicated genes primarily expressed in glomerular podocytes.
Purpose of the Study:
- To investigate the role of the KIRREL1 gene in SRNS pathogenesis.
- To identify genetic mutations associated with SRNS in affected families.
Main Methods:
- Genetic analysis of two unrelated families with SRNS.
- Assessment of KIRREL1 protein localization and function in podocytes.
Main Results:
- Identified homozygous mutations in the KIRREL1 gene in both families.
- Observed that mutant KIRREL1 proteins failed to localize to the podocyte cell membrane.
- Demonstrated defective protein trafficking and impaired podocyte function in affected individuals.
Conclusions:
- Mutations in KIRREL1 are a cause of SRNS.
- KIRREL1 protein is crucial for maintaining podocyte cell membrane integrity and glomerular filtration.
- Defective KIRREL1 function contributes to the pathogenesis of SRNS and progression to chronic kidney disease.
Related Concept Videos
Nephrotic Syndrome I : Introduction
07:38Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome III : Nursing Management
12:40A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Mutations
